Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JX-594 (Pexa-Vec) in Sorafenib-Naïve Advanced HCC
NCT01636284Phase 2Completed
- Sponsor
- Jennerex Therapeutics
- Start
- Jun 2012
- Primary completion
- Jun 2013
- Modality
- Oncolytic Viruses
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus in hepatocellular carcinoma (HCC), sponsored by Jennerex Therapeutics. Primary endpoint: Objective Response Rate at 12 months. Started Jun 2012; status: completed.
02
Drugs
vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01636284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01636284.